Lifecore Biomedical, Inc. LFCR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Lifecore Biomedical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lifecore Biomedical, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lifecore Biomedical, Inc.'s cash & equivalents?
- Lifecore Biomedical, Inc. (LFCR) reported cash & equivalents of $20.8M in Q1 2026.
- How has Lifecore Biomedical, Inc.'s cash & equivalents changed year-over-year?
- Lifecore Biomedical, Inc.'s cash & equivalents increased by 151.6% year-over-year, from $8.27M to $20.8M.
- What is the long-term trend for Lifecore Biomedical, Inc.'s cash & equivalents?
- Over 5 years (2021 to 2026), Lifecore Biomedical, Inc.'s cash & equivalents has grown at a 93.7% compound annual growth rate (CAGR), from $763K to $20.8M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.